Wednesday, July 8, 2026

Patent intelligence · US

US 7413754

Use of extracts of the genus Cimicifugaas organoselective medicines for treating diseases of the genitourinary system caused by sex hormones

granted A61KA61K36/71A61PA61P13/00
Status granted
Linked drugs 3
Pipeline programs 6
Years to expiry 2
Applicant portfolio 52
Patent details — US 7413754
Jurisdiction
US
Status
granted
Grant date
Aug 19, 2008
Expiration
Aug 14, 2028
Applicant
Bionorica AG
Claims
6
CPC classes
A61K, A61K36/71, A61P, A61P13/00
View on Google Patents ↗

Quick answer

US 7413754 (Use of extracts of the genus Cimicifugaas organoselective medicines for treating diseases of the genitourinary system caused by sex hormones) is held by Bionorica AG. Status: granted. Granted Aug 19, 2008. Expires Aug 14, 2028 (2 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Applicant
Bionorica AG
Grant date
Expiration
Claims
6
CPC classes
A61K, A61K36/71, A61P, A61P13/00, A61P13/02, A61P13/08

More from Bionorica AG

Related pharmaceutical patents in our USPTO index.

  1. US 12312339

    Polo like kinase 4 inhibitors

    ORIC PHARMACEUTICALS, INC. · Expires May 22, 2045

    granted
  2. US 12239729

    TRPV3 agonists for the treatment of skin conditions

    Soricimed Biopharma Inc. · Expires Feb 27, 2045

    granted
  3. US 12054556

    Anti-PD-L1 antibody and use thereof

    Oricell Therapeutics Co., Ltd. · Expires Aug 1, 2044

    granted
  4. US 12018043

    CD73 inhibitors

    ORIC PHARMACEUTICALS, INC. · Expires Jun 20, 2044

    granted
  5. US 12005080

    Method for promoting proliferation of immune cells

    Oricell Therapeutics Co., Ltd. · Expires Jun 6, 2044

    granted
  6. US 11993655

    Anti-PD-L1 antibody and use thereof

    Oricell Therapeutics Co., Ltd. · Expires May 23, 2044

    granted
  7. US 11858915

    Polo like kinase 4 inhibitors

    ORIC PHARMACEUTICALS, INC. · Expires Dec 28, 2043

    granted
  8. US 11807658

    CD73 inhibitors

    ORIC PHARMACEUTICALS, INC. · Expires Nov 2, 2043

    granted

Frequently asked questions

What is US patent 7413754?

US 7413754 (Use of extracts of the genus Cimicifugaas organoselective medicines for treating diseases of the genitourinary system caused by sex hormones) is held by Bionorica AG. Status: granted. Granted Aug 19, 2008. Expires Aug 14, 2028 (2 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 7413754?

Bionorica AG is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 52 pharmaceutical patents for this assignee.

When does US 7413754 expire?

Our index shows an expiration date of Aug 14, 2028 (2 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.